Patent classifications
C07C229/36
HALOGENATED BENZYLIDINE DERIVATIVES
Novel Halogenated Benzylidine derivatives are provided which exhibit activity for the treatment of immunological diseases and inflammation
POLYSULFIDE STABILIZATION
The present invention is a new tyrosine derivative described below to inhibit hydrolysis of polysulfide.
The new tyrosine derivative formed according to a chemical formula indicated below, wherein one of a-c is “OH” and the rest are “H”; d is C.sub.nH.sub.2nα, where α is “H” or a “halogen atom,” the halogen atom is preferably “I,” and n is an integer from 1 to 5; and e is (NH).sub.x(CO).sub.yC.sub.zH.sub.2zβ, where x is 1 or 0, y is 1 or 0, z is an integer from 1 to 5, β is “H” or a “halogen atom,”.
##STR00001##
POLYSULFIDE STABILIZATION
The present invention is a new tyrosine derivative described below to inhibit hydrolysis of polysulfide.
The new tyrosine derivative formed according to a chemical formula indicated below, wherein one of a-c is “OH” and the rest are “H”; d is C.sub.nH.sub.2nα, where α is “H” or a “halogen atom,” the halogen atom is preferably “I,” and n is an integer from 1 to 5; and e is (NH).sub.x(CO).sub.yC.sub.zH.sub.2zβ, where x is 1 or 0, y is 1 or 0, z is an integer from 1 to 5, β is “H” or a “halogen atom,”.
##STR00001##
PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF
Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”):
##STR00001##
and precursors thereof.
PROCESS OF PREPARING A PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR, AND PRECURSORS THEREOF
Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”):
##STR00001##
and precursors thereof.
PICOLINAMIDES WITH FUNGICIDAL ACTIVITY
The invention relates to picolinamides of Formula I and their use as fungicides.
##STR00001##
PICOLINAMIDES WITH FUNGICIDAL ACTIVITY
The invention relates to picolinamides of Formula I and their use as fungicides.
##STR00001##
Amino Acid Composition and Method for Catalytic Synthesis of Amino Acid by Means of Energy Radiation
The present invention provides an amino acid composition, and a method for producing amino acids by means of energy irradiation, the method comprises contacting a nanostructure catalyst with at least one nitrogen-containing source, at least one hydrogen-containing source and at least one carbon-containing source, and irradiating the nanostructure catalyst, the nitrogen-containing source, the hydrogen-containing source and the carbon-containing source with energy, to produce the amino acids.
Amino Acid Composition and Method for Catalytic Synthesis of Amino Acid by Means of Energy Radiation
The present invention provides an amino acid composition, and a method for producing amino acids by means of energy irradiation, the method comprises contacting a nanostructure catalyst with at least one nitrogen-containing source, at least one hydrogen-containing source and at least one carbon-containing source, and irradiating the nanostructure catalyst, the nitrogen-containing source, the hydrogen-containing source and the carbon-containing source with energy, to produce the amino acids.
High penetration drugs and their compositions thereof for treatment of Parkinson diseases
One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.